Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma

Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in frontline CLL

A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma

A single dose of ctx001 shows promising efficacy and safety for TDT and severe SCD

Treatment with decitabine resulted in a similar survival and fewer adverse events compared with chemo in older patients with AML

Lack of access to new cancer medicines in LMICs

Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC and active, untreated CNS metastases

Spotlight on global cancer control at ASCO 2022

ASCO 2022: Head and neck cancer highlights

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy